Lilly Just Placed Million Bet on Injectables Boom
Lilly is backing Absci with a $40 million investment as Absci advances ABS-201, a next-gen injectable targeting hair ...
Lilly
Explore four Lilly-focused articles covering stock moves, GLP-1 growth, market impact, and access expansions. Learn how these trends could affect your portfolio and healthcare costs.
8 articles
Lilly Novo Nordisk: Better Weight-Loss Stock Outlook
Two pharma giants sit at the center of the booming weight-loss drug market. This piece breaks down which could offer ...
Lilly Stock Jumps After Phase 3 Weight-Drug Readout
Lilly stock jumps after Phase 3 readout for a next-generation weight-loss drug exceeded expectations. Investors see d...
Is Lilly Starting Nvidia-Style Run? Assessing the Stock Momentum and Risks
Could Lilly ride a Nvidia-like surge? This piece analyzes whether the stock can follow Nvidia’s AI-driven momentum, f...
CVS to Cover Lilly’s GLP-1 Medications, Expanding Access
CVS Health will broaden coverage for Lilly’s GLP-1 medications, including the new pill Foundayo and Zepbound injectio...
Will ASML, Lilly, or TransDigm Be the Next Big Stock Split?
As Wall Street eyes the next stock split, ASML, Lilly, and TransDigm sit near the top of the list. Analysts say the o...
Lilly Just Opened Door to a GLP-1 Growth Boom in Markets
Eli Lilly unveiled a direct-to-employer program for Zepbound, aiming to accelerate GLP-1 adoption and expand market s...
Lilly Stock Slumped Today: Why Shares Fell in Aftermarket
Lilly shares moved lower after Novo Nordisk announced price cuts on leading obesity drugs, signaling a tougher compet...